168 related articles for article (PubMed ID: 8413948)
21. Does levodopa therapy delay death in Parkinson's disease?
Uitti RJ; Ahlskog JE; Maraganore DM
Mov Disord; 1996 May; 11(3):343-4. PubMed ID: 8723162
[No Abstract] [Full Text] [Related]
22. Parkinson's disease: progression and mortality.
Hoehn MM
Adv Neurol; 1987; 45():457-61. PubMed ID: 3825726
[TBL] [Abstract][Full Text] [Related]
23. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.
Fernandez HH; Standaert DG; Hauser RA; Lang AE; Fung VS; Klostermann F; Lew MF; Odin P; Steiger M; Yakupov EZ; Chouinard S; Suchowersky O; Dubow J; Hall CM; Chatamra K; Robieson WZ; Benesh JA; Espay AJ
Mov Disord; 2015 Apr; 30(4):500-9. PubMed ID: 25545465
[TBL] [Abstract][Full Text] [Related]
24. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.
Koller W; Guarnieri M; Hubble J; Rabinowicz AL; Silver D
J Neural Transm (Vienna); 2005 Feb; 112(2):221-30. PubMed ID: 15503197
[TBL] [Abstract][Full Text] [Related]
25. [Stalevo (levodopa/carbidopa/entacapon)--a new generation drug in the treatment of Parkinson's disease].
Fedorova NV; Levin OS; Smolentseva IG; Kulua TK
Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(9):39-46. PubMed ID: 17069061
[TBL] [Abstract][Full Text] [Related]
26. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
Juhász A; Aschermann Z; Ács P; Janszky J; Kovács M; Makkos A; Harmat M; Tényi D; Karádi K; Komoly S; Takáts A; Tóth A; Nagy H; Klivényi P; Dibó G; Dézsi L; Zádori D; Annus Á; Vécsei L; Varannai L; Kovács N
Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758
[TBL] [Abstract][Full Text] [Related]
27. Transcutaneous port for levodopa/carbidopa intestinal gel administration in Parkinson's disease.
van Laar T; Nyholm D; Nyman R
Acta Neurol Scand; 2016 Mar; 133(3):208-15. PubMed ID: 26213103
[TBL] [Abstract][Full Text] [Related]
28. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC
Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047
[TBL] [Abstract][Full Text] [Related]
29. Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa.
Frackiewicz EJ; Jhee SS; Shiovitz TM; Webster J; Topham C; Dockens RC; Whigan D; Salazar DE; Cutler NR
Ann Pharmacother; 2002 Feb; 36(2):225-30. PubMed ID: 11847938
[TBL] [Abstract][Full Text] [Related]
30. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease.
Fernandez HH; Odin P
Curr Med Res Opin; 2011 May; 27(5):907-19. PubMed ID: 21351823
[TBL] [Abstract][Full Text] [Related]
31. Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease.
Hutton JT; Morris JL
Neurology; 1992 Jan; 42(1 Suppl 1):51-6; discussion 57-60. PubMed ID: 1549202
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
Kuoppamäki M; Leinonen M; Poewe W
J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
[TBL] [Abstract][Full Text] [Related]
33. Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease.
Tetrud J; Nausieda P; Kreitzman D; Liang GS; Nieves A; Duker AP; Hauser RA; Farbman ES; Ellenbogen A; Hsu A; Kell S; Khanna S; Rubens R; Gupta S
J Neurol Sci; 2017 Feb; 373():116-123. PubMed ID: 28131167
[TBL] [Abstract][Full Text] [Related]
34. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
35. An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients.
Krüger R; Lingor P; Doskas T; Henselmans JML; Danielsen EH; de Fabregues O; Stefani A; Sensken SC; Parra JC; Onuk K; Yegin A; Antonini A
Adv Ther; 2017 Jul; 34(7):1741-1752. PubMed ID: 28631218
[TBL] [Abstract][Full Text] [Related]
36. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
Verhagen Metman L; Stover N; Chen C; Cowles VE; Sweeney M
Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690
[TBL] [Abstract][Full Text] [Related]
37. Long-term efficacy of controlled-release carbidopa/levodopa in patients with advanced Parkinson's disease.
Mark MH; Sage JI
Ann Clin Lab Sci; 1989; 19(6):415-21. PubMed ID: 2690730
[TBL] [Abstract][Full Text] [Related]
38. Parkinson's disease in Taiwan: an analysis of 215 patients.
Chia LG; Liu LH
Neuroepidemiology; 1992; 11(3):113-20. PubMed ID: 1407246
[TBL] [Abstract][Full Text] [Related]
39. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients.
Slevin JT; Fernandez HH; Zadikoff C; Hall C; Eaton S; Dubow J; Chatamra K; Benesh J
J Parkinsons Dis; 2015; 5(1):165-74. PubMed ID: 25588353
[TBL] [Abstract][Full Text] [Related]
40. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE
Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]